Evidence map›Paper›PMID 19564583›Full record

ArticleNeurology2009

Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis.

R T Naismith, N T Tutlam, J Xu, J B Shepherd, E C Klawiter, S-K Song, A H Cross

Registry-linked trialAbstract readComparative Study
In one paragraph

Article in Neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01337986 (Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis), which is not on this map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01337986 phase2 / phase3completednot on this mapstarted 2011, after this paper: background citation

Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis

TypeinterventionalSponsorWashington University School of MedicineRan2011 to 2013Enrolled53ConditionsMultiple Sclerosis, Optic NeuritisArmsDalfampridine/Placebo, Placebo/Dalfampridine
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Memantine for axonal loss of optic neuritis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2012
    Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Atypical optic neuritis: An overview.Indian journal of ophthalmology · 2021
    Review
  17. Observational
  18. Article
  19. Functional-structural assessment of the optic pathways in patients with optic neuritis.Documenta ophthalmologica. Advances in ophthalmology · 2020
    Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

R T NaismithDepartment of Neurology, Washington University, St Louis, MO 63110, USA. naismithr@neuro.wustl.edu
N T Tutlam
J Xu
J B Shepherd
E C Klawiter
S-K Song
A H Cross

Funding

Washington University Institute of Clinical and Translational Sciences (UL1)UL1RR024992 · NCRR · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2007 to 2011
$45.4M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Diffusion Imaging of Axonal Loss in the Optic NervesK23NS052430 · NINDS · WASHINGTON UNIVERSITY · PI NAISMITH, ROBERT T · 2007 to 2011
$755k
A PHASE ll TRIAL OF RITUXAN IN MULTIPLE SCLEROSISK24RR017100 · NCRR · WASHINGTON UNIVERSITY · PI CROSS, DOROTHY ANNE · 2004 to 2007
$347k
PHARMACOLOGY AND TOXICOLOGY OF ANTITUMOR AGENTSK04CA001012 · NCI · YALE UNIVERSITY · PI LAZO, JOHN S · 1985 to 1989
–
CSR NIH HHS RG 3670NCATS NIH HHS UL1 TR000448NCI NIH HHS CA1012NCRR NIH HHS K12 RR02324902NCRR NIH HHS K24 RR017100NCRR NIH HHS UL1 RR024992NINDS NIH HHS K23 NS052430-01A1
6 · The paper itself

Abstract

objectivesDetermine the utility of optical coherence tomography (OCT) to detect clinical and subclinical remote optic neuritis (ON), its relationship to clinical characteristics of ON and visual function, and whether the retinal nerve fiber layer (RNFL) thickness functions as a surrogate marker of global disease severity.

methodsCross-sectional study of 65 subjects with at least 1 clinical ON episode at least 6 months prior. Measures included clinical characteristics, visual acuity (VA), contrast sensitivity (CS), OCT, and visual evoked potentials (VEP).

resultsNinety-six clinically affected optic nerves were studied. The sensitivity of OCT RNFL after ON was 60%, decreasing further with mild onset and good recovery. VEP sensitivity was superior at 81% (p = 0.002). Subclinical ON in the unaffected eye was present in 32%. VEP identified 75% of all subclinically affected eyes, and OCT identified <20%. RNFL thickness demonstrated linear correlations with VA (r = 0.65) and CS (r = 0.72) but was unable to distinguish visual categories <20/50. RNFL was thinner with severe onset and disease recurrence but was unaffected by IV glucocorticoids. OCT measurements were not related to overall disability, ethnicity, sex, or age at onset. The greatest predictor for RNFL in the unaffected eye was the RNFL in the fellow affected eye.

conclusionsVisual evoked potentials (VEP) remains the preferred test for detecting clinical and subclinical optic neuritis. Optical coherence tomography (OCT) measures were unrelated to disability and demographic features predicting a worse prognosis in multiple sclerosis. OCT may provide complementary information to VEP in select cases, and remains a valuable research tool for studying optic nerve disease in populations.

Indexed as

AdolescentAdultAgedCross-Sectional StudiesElectrodiagnosisElectroencephalographyEvoked Potentials, VisualFemaleHumansMaleMiddle AgedNerve Fibers, MyelinatedNeural ConductionOptic NerveOptic NeuritisPredictive Value of Tests

Identifiers

PMID19564583
PMCPMC2707110

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.